Abstract:BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available. BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available.

Short Hairpin RNA Causes the Methylation of Transforming Growth Factor-Β Receptor II Promoter and Silencing of the Target Gene in Rat Hepatic Stellate Cells

Application of short hairpin RNAs (shRNAs) to study gene function in mammalian systems

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

722. Silencing of Transforming Growth Factor-β Receptor II by RNA Interference Suppresses Extracellular Matrix Production in Rat Hepatic Stellate Cells

Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells

The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells

The experimental study of short hairpin RNA on the suppression of lung cancer-associated gene

RNA Interference-Mediated Knockdown of DNA Methyltransferase 1 Leads to Promoter Demethylation and Gene Re-Expression in Human Lung and Breast Cancer Cells

Enhanced Target Gene Knockdown by a Bifunctional Shrna: a Novel Approach of RNA Interference

An atypical component of RNA-directed DNA methylation machinery has both DNA methylation-dependent and -independent roles in locus-specific transcriptional gene silencing.

RNA interference with small hairpin RNAs transcribed from a human U6 promoter-driven DNA vector.

Stable suppression of gene expression by RNAi in mammalian cells

TALEN/CRISPR-mediated Engineering of a Promoterless Anti-Viral RNAi Hairpin into an Endogenous Mirna Locus

Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment

Knockdown of Human P53 Gene Expression in 293-T Cells by Retroviral Vector-Mediated Short Hairpin Rna

Promoter-targeted siRNAs Induce Gene Silencing of Simian Immunodeficiency Virus (SIV) Infection In Vitro

Transgenic RNA interference in mice.

Stable Suppression of Gene Expression in Murine Embryonic Stem Cells by RNAi Directed from DNA Vector‐Based Short Hairpin RNA

Expression of shRNA From a Tissue-specific pol II Promoter Is an Effective and Safe RNAi Therapeutic

Gene silencing in mammalian cells by PCR-based short hairpin RNA.

A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference